Same Drug, Two FDA Indications, Two Different Doses
The same molecule, the same bottle label at two very different strengths — one dose an antidepressant, the other a genuinely different, FDA-approved sleep drug. The case for confusion here is real, and so is the case for why it matters.
P.C., a 71-year-old woman, taught piano out of her home for over thirty years and still keeps a handful of longtime adult students, a routine that has given her retirement real structure since her husband died two years ago after a long illness. She has lived alone since, in the same house, and describes herself as having adjusted reasonably well to being on her own, though she’s honest that the first year was harder than she let on to her children. Over roughly the past year she has developed a stable, if unwelcome, sleep pattern: falling asleep easily enough at bedtime, but waking reliably around 3 a.m. and staying awake for one to two hours, sometimes longer, before drifting off again.
She has osteoporosis, diagnosed on a routine bone density scan four years ago and managed since with alendronate, along with mild hypertension controlled on a low-dose thiazide. Her physician screened her carefully for depression, given the timing relative to her husband’s death, and found no evidence of a mood disorder — her sleep pattern has stayed essentially unchanged since it began, not worsening or evolving the way a depressive episode typically would. She specifically wants to avoid any medication that increases her fall risk, given her osteoporosis, and mentioned, with visible wariness, that she once took “a form of doxepin, a big dose, years ago for depression” after a difficult period in her forties, and didn’t tolerate it well — real grogginess, a persistently dry mouth — memories that have left her hesitant about anything with that name on the label.
Her physician, reviewing sleep-maintenance-specific options, considered low-dose doxepin (3–6 mg) precisely because it is FDA-approved for this exact problem — sleep-maintenance insomnia, not depression — at a dose roughly fiftyfold lower than the antidepressant range she remembers poorly, and wanted to walk her through carefully why the same drug name on the bottle doesn’t mean the same experience this time.
In clinic, weighing an old bad experience against a new dose
Her wariness is understandable but based on a different drug experience than what’s actually being proposed. At 3–6 mg, doxepin is functioning as a highly H1-selective antihistamine — its antidepressant activity, which depends on norepinephrine and serotonin reuptake inhibition at much higher doses, is essentially absent at this range. The anticholinergic effects she remembers — dry mouth, grogginess — are dose-dependent and were driven by the roughly 50-fold higher dose she took for depression, not an inherent property of the molecule at any dose.
This isn’t an off-label repurposing either — low-dose doxepin (marketed separately as a distinct sleep-maintenance product) carries its own FDA approval specifically for this indication, a genuinely different regulatory status than trazodone’s off-label use in the prior case.
I’d underline the fall-risk piece specifically, since that’s her stated priority. Low-dose doxepin’s selectivity at this dose is exactly why it’s one of the few hypnotics with minimal next-morning residual sedation and no meaningful anticholinergic burden in trials of older adults — a real advantage over zolpidem, which the American Geriatrics Society Beers Criteria specifically flags as a fall-risk medication to avoid or use cautiously in patients over 65.
For a 71-year-old with osteoporosis whose explicit priority is avoiding a fall, that distinction is the actual clinical basis for the choice — not just reassurance about her prior bad experience, but a real difference in the geriatric risk profile between the two options being compared.
Agreed without real disagreement: low-dose doxepin 3 mg started, with an explicit explanation to P.C. of why this dose and indication differ meaningfully from her prior experience — a different drug encounter under the same name, not a repeat of it.
Both voices converged directly on the same recommendation from different angles — the pharmacologist on mechanism-at-dose, the geriatrician on comparative fall risk — and there was no genuine remaining disagreement to carry forward; the narrative itself resolved cleanly once the dose distinction was made explicit.